Delivery Order SPE2DB25D3012-SPE2DB25FWZFH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a common medication used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $11,771.03, is scheduled for completion by August 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through competitive procedures with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. The contract, awarded on August 18, 2025, carries a ceiling value of $2,029.15 with a firm fixed price structure and an ultimate completion date of August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This was a competitively awarded...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. This firm fixed-price delivery order, valued at $24,171.55, is scheduled for completion by September 5, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award was made through open competition with no...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat benign prostatic hyperplasia. This competitive delivery order, valued at $2,750.29 with firm fixed pricing, was awarded on August 6, 2025, with an ultimate completion date of August 7, 2025. The contract includes no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $1,192.79 and a completion date of September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The pharmaceutical will be supplied from the vendor's location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a contract ceiling value of $1,727.65. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by August 8, 2025. The award represents a routine pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly prescribed for benign prostatic hyperplasia treatment, with a contract value of $1,279.81. The award, issued on July 28, 2025, carries a firm fixed price structure with an ultimate completion date of July 29, 2025. The contract represents a non-set-aside award issued through open competition, reflecting AmerisourceBergen's continued qualification...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, valued at $2,702.16. This contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication commonly used to treat urinary symptoms associated with benign prostatic hyperplasia. This non-set-aside, competitively awarded contract is structured as a firm fixed price delivery order with a ceiling value of $5,073.32 and an ultimate completion date of September 5, 2025. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a ceiling value of $18,084.60. This is a firm fixed-price delivery order with no set-aside designation, meaning the contract was awarded through open competition. The pharmaceutical product will be delivered to AmerisourceBergen Drug Corp's location in Conshohocken, Pennsylvania, with an ultimate completion date of August 1,...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWZFHDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, a medication used to treat benign prostatic hyperplasia. The contract is firm fixed price with a ceiling value of $10,078.41 and an ultimate completion date of August 15, 2025. This is a non-set-aside competitive award, with performance to be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, holds a significant position as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's prime IDC with DLA serves as a comprehensive global pharmaceutical support vehicle enabling supply of diverse pharmaceutical products, vaccines, and medical supplies across multiple therapeutic domains. This delivery order represents one of numerous small-to-moderate value transactions issued under this vehicle, demonstrating the contractor's capacity to fulfill federal medical supply requirements across a broad range of pharmaceutical commodities for Defense Health Agency and other government healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 8/14/25 |